



Retraction: Exosomal MicroRNA-221-3p Confers Adriamycin Resistance in Breast Cancer Cells by Targeting PIK3R1

OPEN ACCESS

Approved by:

Giuseppe Giaccone,
Cornell University, United States

*Correspondence:

Frontiers Editorial Office
editorial.office@frontiersin.org

Specialty section:

This article was submitted to
Cancer Genetics,
a section of the journal
Frontiers in Oncology

Received: 20 December 2021

Accepted: 20 December 2021

Published: 30 December 2021

Citation:

Frontiers Editorial Office (2021)
Retraction: Exosomal MicroRNA-
221-3p Confers Adriamycin
Resistance in Breast Cancer
Cells by Targeting PIK3R1.
Front. Oncol. 11:839904.
doi: 10.3389/fonc.2021.839904

Frontiers Editorial Office*

A Retraction of the Original research Article

Exosomal MicroRNA-221-3p Confers Adriamycin Resistance in Breast Cancer Cells by Targeting PIK3R1

By Pan X., Hong X., Lai J., Cheng L., Cheng Y., Yao M., Wang R. and Hu N. (2020) *Front. Oncol.* 10:441. doi: 10.3389/fonc.2020.00441

The journal and Chief Editors retract the 30 April 2020 article cited above.

Following publication, concerns were raised regarding the validity of the data in the article. The authors failed to provide the raw data or a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers' policies. Given the concerns, and the lack of raw data, the editors no longer have confidence in the findings presented in the article.

This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers. The authors have not responded to any correspondence regarding the retraction.

Copyright © 2021 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.